Document Detail


Duloxetine: a dual serotonin-norepinephrine reuptake inhibitor for treatment of major depressive disorder.
MedLine Citation:
PMID:  15843287     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The burden of mental illness has been underestimated worldwide. Depression was the fourth leading cause of disease burden in the world in 1990 and is projected to be the second leading cause of disability by 2020. It is a leading cause of morbidity and mortality in the United States, costing billions of dollars annually in direct and indirect medical costs and losses in productivity. Patients with major depressive disorder (MDD) may experience both psychological and medical complaints, including somatic sensations or pain. Some antidepressants have been shown to treat chronic pain syndromes, but despite the variety of antidepressants available in the United States, only 65-70% of patients respond to initial antidepressant treatment. Treatments are limited by delayed onset of antidepressant effects, side effects, partial response, and treatment resistance. Duloxetine, approved by the U.S. Food and Drug Administration for the treatment of MDD, is a reuptake inhibitor at serotonergic and noradrenergic neurons and appears to have low affinity for other neurotransmitter systems. In clinical trials, duloxetine was effective for the treatment of MDD and was well tolerated. Further study is needed to compare its efficacy with that of other antidepressants, to clarify effects on somatic symptoms, and to assess potential adverse cardiovascular and sexual side effects. Duloxetine is also approved for the management of diabetic peripheral neuropathic pain and is under investigation for the treatment of stress urinary incontinence in women.
Authors:
Jennifer L Kirwin; Jessica L Gören
Related Documents :
20397587 - Factors impacting the selection of antidepressant treatment in patients with major depr...
8580387 - Late-life delusional depression: acute and long-term treatment.
12806567 - Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinic...
7624387 - Paroxetine as antidepressant in combined antidepressant-neuroleptic therapy in delusion...
10071537 - Bladder contractility and idiopathic detrusor instability in the female.
20709517 - Montelukast added to fluticasone propionate does not alter inflammation or outcomes.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Pharmacotherapy     Volume:  25     ISSN:  0277-0008     ISO Abbreviation:  Pharmacotherapy     Publication Date:  2005 Mar 
Date Detail:
Created Date:  2005-04-21     Completed Date:  2005-05-18     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8111305     Medline TA:  Pharmacotherapy     Country:  United States    
Other Details:
Languages:  eng     Pagination:  396-410     Citation Subset:  IM    
Affiliation:
Department of Pharmacy Practice, Bouvé College of Health Sciences, Northeastern University, Boston, Massachusetts, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Depressive Disorder, Major / drug therapy*
Drug Interactions
Humans
Middle Aged
Randomized Controlled Trials as Topic
Serotonin Uptake Inhibitors / pharmacology*,  therapeutic use*
Thiophenes / pharmacology*,  therapeutic use*
Chemical
Reg. No./Substance:
0/Serotonin Uptake Inhibitors; 0/Thiophenes; 116539-58-3/duloxetine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Tactics for vascular protection after acute ischemic stroke.
Next Document:  The use of tricyclic antidepressants and selective serotonin reuptake inhibitors in women who are br...